Previous 10 | Next 10 |
Pharmaceuticals and biotechnology are cheap relative to 11-year valuation averages. Life science tools and healthcare equipment are overvalued. IXJ: a global alternative to XLV. 10 stocks cheaper than their peers in May. For further details see: IXJ: Healthcare Dashb...
Silver Ring Value Partners provides investment advisory services. The Company offers portfolio management, financial planning, and trading services. Silver Ring Value Partners serves investors in the State of Massachusetts. The portfolio’s market value is roughly unchanged thus...
Innoviva press release (NASDAQ:INVA): Q1 GAAP EPS of $0.20. Revenue of $90.06M (+5.3% Y/Y) beats by $3.66M. For further details see: Innoviva GAAP EPS of $0.20, revenue of $90.06M beats by $3.66M
Royalties increased by 5% to $93.5 million in the first quarter of 2022, compared to the same quarter in 2021. Issued $261.0 million convertible senior notes due 2028 and repurchased a portion of the convertible subordinated notes due 2023. Invested $45.0 million into Armata P...
Pharmaceuticals and biotechnology still are attractive regarding value and quality. Other subsectors are overvalued by 15% to 42% relative to 11-year averages. Fast facts on IBB. 10 healthcare stocks cheaper than their peers in April. For further details see: IBB: He...
Shares of Innoviva Inc. (NASDAQ:INVA) traded today at $20.69, eclipsing its 52-week high. This new high was reached on below average trading volume as 135,000 shares traded hands, while the average 30-day volume is approximately 1.3 million shares. Innoviva Inc. (NASDAQ:INVA) is currentl...
Armata Pharmaceuticals Announces Closing of Second and Final Tranche of $45 Million Private Placement with Innoviva PR Newswire MARINA DEL REY, Calif. , March 31, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or th...
Pharma/biotech is undervalued by about 14% relative to 11-year averages. Life science tools and healthcare equipment are overvalued by over 25%. Focus on IXJ: a more diversified alternative to XLV. 10 stocks cheaper than their peers in March. For further details see: ...
The pharmaceutical business can be challenging for companies and investors as money is poured into developing drugs that may or may not achieve U.S. Food and Drug Administration (FDA) or international approval to market and sell. Innoviva (NASDAQ: INVA) approaches investing in...
Innoviva (NASDAQ:INVA) priced its upsized offering of $225M principal amount of the 2.125% convertible senior notes due 2028; size of offering was increased from earlier announced $200M. Initial purchasers to be granted 13-days option to purchase up to an additional $45M principal amount...
News, Short Squeeze, Breakout and More Instantly...
Innoviva, Inc. (Nasdaq: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strate...